803712-79-0 Obatoclax mesylate AKSci V2454
 
 
Loading Please Wait...
  V2454    AKSci Reference Standard
Obatoclax mesylate, 98% (HPLC), powder
 
GX15-070
IDENTITY
CAS Number:803712-79-0
MDL Number:MFCD18074508
MF:C20H19N3O.CH4O3S
MW:413.49
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC), powder
Physical Form (at 20°C):Solid
Melting Point:228-233°C
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:III
A hazmat fee may apply to certain package sizes. Please check pricing table for an indicator of applicable hazmat fees.

BIOLOGICAL INFO
Solubility:DMSO
Application(s):Iinhibitor of the Bcl-2 family of proteins
Form:Mesylate
Research Area:Cancer

REVIEW
 Obatoclax is an experimental drug candidate for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon. It is in Phase II clinical trials for the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis. Obatoclax is an inhibitor of the Bcl-2 family of proteins. is a novel Bcl-2 homology domain-3 (BH3) mimetic. This inhibition induces apoptosis in cancer cells, preventing tumor growth.

REFERENCES
[1]Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 1;68(9):3413-20.
[2] Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34.
[3] Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008 Dec 15;14(24):8295-301.
[4] Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008 Dec 15;14(24):8295-301.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of April 20, 2024

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives >


PubChem
  @PubMed